Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO trial. …
Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial
January 22, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review - 12 September
September 12, 2025 - - Podcast -
Surely this is what the collapse of moral authority must look like
September 11, 2025 - - Latest News -
Artificial Intelligence can only accelerate Health Technology Assessments
September 11, 2025 - - Latest News -
Australian biotechs shine at Asia Pacific Cell and Gene Therapy Awards
September 11, 2025 - - Australian Biotech -
Trump administration announces new disclosure rules for medicine advertising
September 10, 2025 - - Latest News -
Chemist Warehouse partners with DoorDash to deliver health and beauty on demand
September 10, 2025 - - Latest News -
Cancer leaders unite to tackle equity and innovation at 2025 PCPA Summit
September 10, 2025 - - Latest News